Trial record 2 of 26 for:    "Osteogenesis Imperfecta"

Bisphosphonate Treatment of Osteogenesis Imperfecta

This study has been completed.
Information provided by:
Novartis Identifier:
First received: June 27, 2003
Last updated: April 26, 2012
Last verified: April 2012
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.

Condition Intervention Phase
Osteogenesis Imperfecta
Drug: Zoledronic Acid
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bisphosphonate Treatment of Osteogenesis Imperfecta

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change in lumbar spine bone mineral density at month 12 relative to baseline

Secondary Outcome Measures:
  • Change in Z score of the lumbar spine at month 12 relative to baseline

Estimated Enrollment: 158
Study Start Date: June 2003
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   3 Months to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Male or Female children between 3 months and 17 years old
  • OI type I, III or IV


  • Deformity or abnormality which would prevent spine bone density from being done
  • Any surgical bone-lengthening procedure
  • Any kidney diseases or abnormalities
  • Low calcium or vitamin D levels in the blood

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00063479

United States, California
UCLA - Division of Pediatric Nephrology
Los Angeles, California, United States, 90024
United States, Delaware
Alfred I. DuPont Hospital for Children
Wilmington, Delaware, United States, 19899
United States, Idaho
Intermountain Orthopedics
Boise, Idaho, United States, 83702
United States, Illinois
St. Jude Children's Research Hospital
Peoria, Illinois, United States, 61637
United States, Nebraska
Children's Hospital
Omaha, Nebraska, United States, 68198
United States, Ohio
Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Children's Hospital
Columbus, Ohio, United States, 43205
United States, Oregon
Oregon Health Sciences University
Portland, Oregon, United States, 97201
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
Texas Children's Hosptial
Houston, Texas, United States, 77030
Sponsors and Collaborators
Novartis Pharmaceuticals
  More Information Identifier: NCT00063479     History of Changes
Other Study ID Numbers: CZOL446H2202 
Study First Received: June 27, 2003
Last Updated: April 26, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Osteogenesis Imperfecta
bone markers
bone loss
brittle bone disease

Additional relevant MeSH terms:
Osteogenesis Imperfecta
Bone Diseases
Bone Diseases, Developmental
Collagen Diseases
Connective Tissue Diseases
Genetic Diseases, Inborn
Musculoskeletal Diseases
Zoledronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on May 24, 2016